NMTC vs. CEMI, CHEK, BLUA, KRMD, BWAY, SRTS, HSAQ, ALUR, NVNO, and PDEX
Should you be buying NeuroOne Medical Technologies stock or one of its competitors? The main competitors of NeuroOne Medical Technologies include Chembio Diagnostics (CEMI), Check-Cap (CHEK), BlueRiver Acquisition (BLUA), KORU Medical Systems (KRMD), BrainsWay (BWAY), Sensus Healthcare (SRTS), Health Sciences Acquisitions Co. 2 (HSAQ), Allurion Technologies (ALUR), enVVeno Medical (NVNO), and Pro-Dex (PDEX). These companies are all part of the "medical" sector.
NeuroOne Medical Technologies (NASDAQ:NMTC) and Chembio Diagnostics (NASDAQ:CEMI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, community ranking, dividends, profitability and institutional ownership.
In the previous week, NeuroOne Medical Technologies had 1 more articles in the media than Chembio Diagnostics. MarketBeat recorded 1 mentions for NeuroOne Medical Technologies and 0 mentions for Chembio Diagnostics. NeuroOne Medical Technologies' average media sentiment score of 1.89 beat Chembio Diagnostics' score of 0.00 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.
Chembio Diagnostics received 210 more outperform votes than NeuroOne Medical Technologies when rated by MarketBeat users. However, 71.59% of users gave NeuroOne Medical Technologies an outperform vote while only 53.22% of users gave Chembio Diagnostics an outperform vote.
NeuroOne Medical Technologies has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Chembio Diagnostics has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500.
NeuroOne Medical Technologies has higher earnings, but lower revenue than Chembio Diagnostics. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Chembio Diagnostics, indicating that it is currently the more affordable of the two stocks.
NeuroOne Medical Technologies currently has a consensus price target of $2.20, suggesting a potential upside of 136.58%. Given NeuroOne Medical Technologies' higher possible upside, research analysts clearly believe NeuroOne Medical Technologies is more favorable than Chembio Diagnostics.
Chembio Diagnostics has a net margin of -47.03% compared to NeuroOne Medical Technologies' net margin of -343.55%. Chembio Diagnostics' return on equity of -113.57% beat NeuroOne Medical Technologies' return on equity.
16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 8.6% of Chembio Diagnostics shares are held by institutional investors. 7.5% of NeuroOne Medical Technologies shares are held by company insiders. Comparatively, 3.3% of Chembio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
NeuroOne Medical Technologies beats Chembio Diagnostics on 10 of the 17 factors compared between the two stocks.
Get NeuroOne Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NMTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroOne Medical Technologies Competitors List
Related Companies and Tools
